CD274 and non-small cell lung carcinoma: The PK properties of pembrolizumab, an immune checkpoint–blocking monoclonal antibody, were characterized through a two-compartment analysis of pooled data from various clinical trials, revealing no significant covariate effects and validating the dosing regimen of 2 mg/kg every three weeks, and this dosage was approved for treating inoperable or metastatic melanoma and non-small cell lung cancer (NSCLC) through targeting the immune checkpoint protein, programmed death-ligand 1 (PD-L1) [57].